Kenalog (Triamcinolone Acetonide)

Triamcinolone acetonide binds to intracellular glucocorticoid receptors, forming a complex that moves into the cell nucleus. There it alters gene transcription, increasing anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines, thereby reducing swelling, pain, and immune activity.

The dosage of Kenalog is individualized by the prescribing clinician based on the specific indication, patient weight, severity of disease, and response to therapy. Only a qualified health professional should determine the appropriate dose and treatment schedule.

Safety data for Kenalog in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a healthcare provider after careful assessment.

To order Kenalog, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kenalog (triamcinolone acetonide) is a potent intermediate‑acting corticosteroid with strong anti‑inflammatory properties. Compared with dexamethasone, it has a slightly longer duration of action, while relative to hydrocortisone it is more potent on a milligram‑per‑milligram basis, making it suitable for acute, high‑intensity inflammation.

Kenalog must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use, and discard any solution that appears discolored or contains particles.

Kenalog is administered by intravenous injection or infusion under the supervision of a qualified healthcare professional. The exact route (slow IV push or diluted infusion) and rate are determined by the prescriber according to the clinical situation and patient tolerance.

Serious risks include adrenal suppression, severe infections, osteonecrosis, cataracts or glaucoma, and rare anaphylactic reactions. Patients should be monitored for signs of infection, unexplained weight gain, visual changes, and symptoms of adrenal insufficiency, especially after abrupt discontinuation.

Kenalog is contraindicated in patients with systemic fungal infections, known hypersensitivity to triamcinolone or any formulation component, and those receiving live vaccines. Caution is also advised for individuals with uncontrolled diabetes, severe hypertension, or active peptic ulcer disease.